LP
CRBP icon

LMR Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

LMR Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,000
Closed -$506K – 1560
2025
Q3 		$506K Buy
+40,000
New +$380K ﹤0.01% 1086

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

LMR Partners's CRBP Position: Q2 2026 in Review

LMR Partners opened a new position in Corbus Pharmaceuticals (CRBP) in Q2 2026: 35,500 shares worth $333K. The stake represents ﹤0.01% of the portfolio and ranks #1247 among its holdings. This is a return to the name: LMR Partners previously reported a position in CRBP as recently as Q2 2021.

LMR Partners first reported a position in CRBP in Q2 2021 and has held it in 2 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • LMR Partners held 35,500 shares of Corbus Pharmaceuticals worth $333K as of Q2 2026.
  • Corbus Pharmaceuticals was a new LMR Partners position in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1247 holding.
  • LMR Partners first reported a position in Corbus Pharmaceuticals in Q2 2021 and has held it in 2 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.